Investor Letter July 2021

Ingemar Kihlström, Chairman of the Board, and Johan Folkunger, CEO, reflect on a strong commitment and combined expertise and Homer Pien, recently appointed Board member of SpectraCure, is introduced.

Investor letter July 2021 is attached.

 

For further information, please contact:

Johan Folkunger, SpectraCures CEO, e-mail: jf@spectracure.com

Please also visit, www.spectracure.com


SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer. The hope is to be able to treat other cancers such as breast cancer in the future, pancreas, and head and neck cancer. The approach is based on PDT treatment combined with a proprietary and patented dose planning platform, the IDOSE® software, which makes it possible to control the laser light dose so that the tumour the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to interstitial PDT treatment accurate, precise and safe for every patient. The goal is that in addition to being free of
tumour, to maintain their quality of life, with limited side effects. We conduct clinical trials as an important in the further development of the company's treatment system.

The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, ca@gwkapital.se, tel +468-503 00 050, and trades under the ticker SPEC.